C
Carmen Altisent
Researcher at Hebron University
Publications - 64
Citations - 2474
Carmen Altisent is an academic researcher from Hebron University. The author has contributed to research in topics: Haemophilia & Haemophilia A. The author has an hindex of 24, co-authored 64 publications receiving 2221 citations. Previous affiliations of Carmen Altisent include University of Barcelona.
Papers
More filters
Journal ArticleDOI
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study
Stylianos E. Antonarakis,J. P. Rossiter,M. Young,J. Horst,P. De Moerloose,S. S. Sommer,Rhett P. Ketterling,H. H. Kazazian,Claude Negrier,Christine Vinciguerra,Jane Gitschier,Michel Goossens,E. Girodon,N. Ghanem,F. Plassa,Jean-Maurice Lavergne,M. Vidaud,J. M. Costa,Y. Laurian,S. W. Lin,S. R. Lin,M. C. Shen,David Lillicrap,Sherryl A. M. Taylor,S. Windsor,Sophie Valleix,K. Nafa,Y. Sultan,Marc Delpech,Cindy L. Vnencak-Jones,John A. Phillips,Rolf Ljung,E. Koumbarelis,A. Gialeraki,T. Mandalaki,P. V. Jenkins,Peter William Collins,K. J. Pasi,Anne Goodeve,Ian R. Peake,F. E. Preston,Marianne Schwartz,Elma Scheibel,Jørgen Ingerslev,David Neil Cooper,David Stuart Millar,V. V. Kakkar,F. Giannelli,J.A. Naylor,E. F. Tizzano,M. Baiget,M. Domenech,Carmen Altisent,J. Tusell,M. Beneyto,J. I. Lorenzo,Christine Gaucher,Claudine Mazurier,Kathelijne Peerlinck,Gert Matthijs,Jj. Cassiman,Jozef Vermylen,P. G. Mori,M. Acquila,D. Caprino,Hiroshi Inaba +65 more
TL;DR: The presence of factor VII inversions is not a major predisposing factor for the development of factor VIII inhibitors; however, slightly more patients with severe hemophilia A and factor VIII inversions develop inhibitors than patients without inversions.
Journal ArticleDOI
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
Samantha C. Gouw,H. Marijke van den Berg,Krista Fischer,Guenter Auerswald,Manuel Carcao,Elizabeth Chalmers,Hervé Chambost,Karin Kurnik,Ri Liesner,Pia Petrini,Helen Platokouki,Carmen Altisent,Johannes Oldenburg,Beatrice Nolan,Rosario Perez Garrido,M Elisa Mancuso,Anne Rafowicz,Michael Williams,Niels Clausen,Rutger A. Middelburg,Rolf Ljung,Johanna G. van der Bom +21 more
TL;DR: It is suggested that in previously untreated patients with severe hemophilia A, high-dosed intensive FVIII treatment increases inhibitor risk and prophylactic FV III treatment decreases inhibitor risk, especially in patients with low-risk F8 mutations.
Journal ArticleDOI
Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age.
TL;DR: In conclusion, patient age at initial treatment appears to influence inhibitor formation, and if confirmed, this finding would have a major impact on the management of haemophilia.
Journal ArticleDOI
Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial
Elena Santagostino,Uri Martinowitz,Toshko Lissitchkov,Brigitte Pan-Petesch,Hideji Hanabusa,Johannes Oldenburg,Lisa N. Boggio,Claude Negrier,Ingrid Pabinger,Mario von Depka Prondzinski,Carmen Altisent,Giancarlo Castaman,Koji Yamamoto,María Teresa Álvarez-Román,Christine Voigt,Nicole Blackman,Iris Jacobs +16 more
TL;DR: Results indicate rIX-FP is safe and effective for preventing and treating bleeding episodes in patients with hemophilia B at dosing regimens of 40IU/kg weekly and 75 IU/kg every 2 weeks.
Journal ArticleDOI
Non‐genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report
Jan Astermark,Carmen Altisent,Angelika Batorova,M. J. Diniz,Alessandro Gringeri,Pål Andre Holme,A. Karafoulidou,M. F. Lopez-Fernandez,Birgit M. Reipert,A Rocino,Mario Schiavoni,M. von Depka,Jerzy Windyga,Karin Fijnvandraat +13 more
TL;DR: A comprehensive review of clinical studies relating to several non‐genetic risk factors and a survey of opinion concerning their importance and clinical influence, conducted among the members of the European Haemophilia Treatment Standardisation Board are presented.